Biodexa Pharmaceuticals Management

Management criteria checks 3/4

Biodexa Pharmaceuticals' CEO is Stephen Stamp, appointed in Sep 2019, has a tenure of 4.58 years. total yearly compensation is £252.00K, comprised of 99.2% salary and 0.8% bonuses, including company stock and options. directly owns 0% of the company’s shares, worth $4.45. The average tenure of the management team and the board of directors is 3 years and 7 years respectively.

Key information

Stephen Stamp

Chief executive officer

UK£252.0k

Total compensation

CEO salary percentage	99.2%
CEO tenure	4.6yrs
CEO ownership	0.0001%
Management average tenure	3yrs
Board average tenure	7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Stephen Stamp's remuneration changed compared to Biodexa Pharmaceuticals's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	UK£252k	UK£250k	-UK£7m
Sep 30 2023	n/a	n/a	-UK£8m
Jun 30 2023	n/a	n/a	-UK£8m
Mar 31 2023	n/a	n/a	-UK£8m
Dec 31 2022	UK£238k	UK£236k	-UK£8m
Sep 30 2022	n/a	n/a	-UK£7m
Jun 30 2022	n/a	n/a	-UK£5m
Mar 31 2022	n/a	n/a	-UK£5m
Dec 31 2021	UK£329k	UK£187k	-UK£5m
Sep 30 2021	n/a	n/a	-UK£7m
Jun 30 2021	n/a	n/a	-UK£8m
Mar 31 2021	n/a	n/a	-UK£15m
Dec 31 2020	UK£193k	UK£175k	-UK£22m
Jun 30 2020	n/a	n/a	-UK£22m
Mar 31 2020	n/a	n/a	-UK£16m
Dec 31 2019	UK£207k	UK£50k	-UK£9m

Compensation vs Market: Stephen's total compensation ($USD315.35K) is below average for companies of similar size in the US market ($USD668.06K).

Compensation vs Earnings: Stephen's compensation has increased whilst the company is unprofitable.

CEO

Stephen Stamp (61 yo)

4.6yrs

Tenure

UK£252,003

Compensation

Mr. Stephen A. Stamp serves as Chief Financial Officer and Director of Biodexa Pharmaceuticals Plc (formerly known as Midatech Pharma plc) since September 9, 2019. He serves as Chief Executive Officer at B...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Stephen Stamp	CEO, CFO	4.6yrs	UK£252.00k	0.00014% £ 4.4
Dmitry Zamoryakhin	Chief Scientific Officer & Chief Medical Officer	2.8yrs	UK£238.36k	0% £ 0
Daniel Palmer	Vice President of Technology	3.3yrs	no data	no data
Nicola Tuckwell	VP & Head of Clinical Operations	less than a year	no data	no data
Fiona Sharp	Group Financial Controller	no data	no data	no data

3.0yrs

Average Tenure

Experienced Management: BDRX's management team is considered experienced (3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Stephen Stamp	CEO, CFO	4.6yrs	UK£252.00k	0.00014% £ 4.4
Simon Turton	Senior Independent Non-Executive Director	9.3yrs	UK£31.54k	0.00014% £ 4.4
Stephen Parker	Independent Non-Executive Chairman	1.8yrs	UK£82.00k	no data
Daniel McCurdy	Member of Scientific Advisory Board	no data	no data	no data
Sijmen de Vries	Independent Non-Executive Director	19.5yrs	UK£31.92k	0.000070% £ 2.2
Michael Natan	Member of Scientific Advisory Board	no data	no data	no data
Francesco Stellaci	Chairman of Scientific Advisory Board	no data	no data	no data
David Male	Member of Scientific Advisory Board	no data	no data	no data
Lorraine O'Driscoll	Member of Scientific Advisory Board	no data	no data	no data
Soledad Penades	Member of Scientific Advisory Board	no data	no data	no data
Jean-Christophe Roux	Member of Scientific Advisory Board	no data	no data	no data
Silke Krol	Member of Scientific Advisory Board	no data	no data	no data

7.0yrs

Average Tenure

64yo

Average Age

Experienced Board: BDRX's board of directors are considered experienced (7 years average tenure).

Biodexa Pharmaceuticals Management

Management criteria checks 3/4

Key information

Recent management updates

Biodexa Appoints Ann Merchant to the Board of Directors

Biodexa Pharmaceuticals Plc, Annual General Meeting, Jun 14, 2023

Midatech Pharma PLC Announces Directorate Change

Midatech Pharma plc Announces Retirement of Rolf Stahel

Midatech Pharma plc, Annual General Meeting, Jun 20, 2022

Recent updates

Full year 2023 earnings released: UK£8.00 loss per share (vs UK£620 loss in FY 2022)

New minor risk - Financial data availability

Biodexa Pharmaceuticals Plc's MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers

New major risk - Share price stability

Biodexa Pharmaceuticals plc Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update

New major risk - Financial position

Biodexa Pharmaceuticals plc Reports 12 Month Survival in Magic-G1 Study of Mtx110 in Recurrent Glioblastoma Patients

Biodexa Appoints Ann Merchant to the Board of Directors

Biodexa Pharmaceuticals Plc has completed a Composite Units Offering in the amount of $5.217389 million.

First half 2023 earnings released: UK£14.39 loss per share (vs UK£249 loss in 1H 2022)

Biodexa Pharmaceuticals plc Completes Recruitment of Cohort A in Study of Mtx110 in Patients with Recurrent Glioblastoma

Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of Mtx-110 (Magic-G1 Study) in Patients with Recurrent Glioblastoma At 2023 Annual European Association of Neuro-Oncology Meeting (Eano)

Biodexa Regain Compliance with Nasdaq Minimum Bid Price Requirement

Biodexa Ltd Announces Completion of Enrolment and Treatment in the Phase 1 Study of Mtx110 in the Treatment of Children with Newly Diagnosed Diffuse Midline Gliomas (Dmgs)

Biodexa Pharmaceuticals Announces Results of Appeal of Delisting Determination

Biodexa Pharmaceuticals plc Announces the Publication of the Results of an Investigator-Initiated Phase I Study Pnoc015

Biodexa Pharmaceuticals Receives a Period of 180 Calendar Days to Return to Compliance with the Minimum Bid Price Rule

Biodexa Pharmaceuticals Receives Staff Determination Letter from Nasdaq to Delist its Securities from The Nasdaq Capital Market Regarding Non-Compliance with the Minimum Bid Price Requirements

Biodexa Pharmaceuticals Plc announced that it has received $3.320388 million in funding

Biodexa Pharmaceuticals Plc, Annual General Meeting, Jun 14, 2023

Biodexa Pharmaceuticals Plc (NasdaqCM:BDRX) entered into non-binding letter of intent to acquire Varian Biopharmaceuticals Inc. for $3.7 million.

Full year 2022 earnings released: UK£0.077 loss per share (vs UK£1.36 loss in FY 2021)

Midatech Pharma plc announced that it has received $5.999223 million in funding

Midatech Pharma Announces Receipt of NASDAQ Notice

Midatech Pharma PLC Announces Planned Dose Escalation in MTX-110 Phase 1 Study

Midatech Pharma plc (AIM:MTPH) entered into a definitive agreement to acquire Bioasis Technologies Inc. (TSXV:BTI) from The Lind Partners, LLC and others for $5.5 million.

Midatech Pharma plc announced that it expects to receive $10 million in funding

Midatech Pharma plc Announces First Patient Enrolled in Phase 1 Study of MTX-110

Midatech Pharma plc Announces Receipt of Nasdaq Notification

Midatech Pharma regains compliance with Nasdaq's minimum bid price requirement

Midatech Pharma reports 1H results

Midatech Pharma PLC Announces Directorate Change

Midatech Pharma plc Announces MTX110 Study to be Presented at ISPNO 2022

Midatech Pharma plc Announces Retirement of Rolf Stahel

Midatech Pharma plc Announces Fast Track Designation Granted to Mtx110 Development for the Treatment of Recurrent Glioblastoma

Midatech Pharma plc, Annual General Meeting, Jun 20, 2022

Midatech Pharma Received Written Notification from Nasdaq Stating Company Is Not in Compliance with Minimum Bid Price Requirement

Midatech Pharma PLC Announces Investigational New Drug Application for Study of MTX110 in Recurrent Glioblastoma (GBM) Becomes Effective

Midatech Pharma plc has completed a Follow-on Equity Offering in the amount of £10 million.

Midatech Pharma plc Announces Shut Down of its Bilbao Operations

Midatech surges on the promise of drug delivery system

Midatech Pharma PLC to Present MTX110 Programmes at The International Symposium on Pediatric Neuro-Oncology, Karuizawa, Japan

Midatech Pharma plc Announces Headline Results of MTX110 Phase I DIPG Study

Midatech Pharma plc to Report First Half, 2020 Results on Sep 10, 2020

Midatech Pharma plc has completed a Follow-on Equity Offering in the amount of £5 million.

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age